Archive 2005

• Exhibition
• Press release
• General information

News		Date
Alnylam Grants Eurogentec License to Fundamental RNAi Patents in the Research Products Market Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has granted Eurogentec, a leading provider of genomics research solutions, a non-exclusive license to provide research products and services in RNA interference (RNAi) under the Kreutzer-Limmer patent family owned by Alnylam. This patent family covers short interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells. read more >>		July 2005
Eurogentec takes part in the Universal Vaccine project. Eurogentec and other leading scientists combine efforts to develop new vaccines. read more >>		June 2005
Proteo Biotech AG to go to clinical trials with Elafin and selects Eurogentec for cGMP manufacturing Proteo Biotech selects Eurogentec for the manufacturing of its clinical trial material, Elafin read more >>		April 2005